Oppenheimer Asset Management Inc. Purchases New Position in Repligen Corporation $RGEN

Oppenheimer Asset Management Inc. purchased a new stake in shares of Repligen Corporation (NASDAQ:RGEN) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 46,326 shares of the biotechnology company’s stock, valued at approximately $6,321,000. Oppenheimer Asset Management Inc. owned approximately 0.08% of Repligen at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Wasatch Advisors LP raised its holdings in shares of Repligen by 27.9% during the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock worth $216,974,000 after acquiring an additional 346,720 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in shares of Repligen by 11.8% in the second quarter. Handelsbanken Fonder AB now owns 22,070 shares of the biotechnology company’s stock valued at $3,011,000 after purchasing an additional 2,332 shares in the last quarter. Everhart Financial Group Inc. bought a new stake in Repligen in the second quarter worth $303,000. Assenagon Asset Management S.A. bought a new stake in Repligen in the second quarter worth $9,687,000. Finally, Balefire LLC purchased a new stake in Repligen during the second quarter valued at $275,000. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on RGEN shares. Jefferies Financial Group reiterated a “hold” rating and set a $142.00 price objective on shares of Repligen in a research report on Tuesday, May 5th. HSBC reduced their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. JPMorgan Chase & Co. increased their price target on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Wolfe Research started coverage on Repligen in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price target for the company. Finally, Royal Bank Of Canada assumed coverage on Repligen in a research report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Repligen currently has an average rating of “Buy” and a consensus target price of $166.43.

Insider Buying and Selling

In related news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.60% of the company’s stock.

Repligen Stock Down 0.4%

Shares of RGEN opened at $166.83 on Friday. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The business has a fifty day moving average of $142.70 and a 200 day moving average of $131.32. The company has a market cap of $9.42 billion, a PE ratio of 228.53, a P/E/G ratio of 3.04 and a beta of 1.03. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, sell-side analysts expect that Repligen Corporation will post 2.06 EPS for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.